APA (7th ed.) Citation

Makoto Nishio, M., Takashi Seto, M., Martin Reck, P., Edward B. Garon, M., Kazuto Nishio, M., Kazuo Kasahara, M., . . . Kazuhiko Nakagawa, M. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset. Elsevier.

Chicago Style (17th ed.) Citation

Makoto Nishio, MD, et al. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset. Elsevier.

MLA (9th ed.) Citation

Makoto Nishio, MD, et al. Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset. Elsevier.